Table 1.
Characteristics of the study group.
| Variable | Value |
|---|---|
| Age [years], mean ± SD Min-Max 95% CI |
36.27 ± 9.60 18–66 34.70–37.80 |
| Sex, n (%) Female Male |
123 (80.92) 29 (19.08) |
| Education, n (%) Basic or vocational education Secondary education Higher education |
7 (4.61) 62 (36.18) 83 (59.21) |
| Place of residence, n (%) Village City > 100 thousand inhabitants 100–500 thousand inhabitants <500 thousand inhabitants |
19 (12.50) 52 (34.21) 39 (25.66) 42 (27.63) |
| Professional activity, n (%) Student Employed Unemployed Disability Retirement pension |
11 (7.24) 98 (64.47) 8 (5.26) 32 (21.05) 3 (1.97) |
| Material status (subjective assessment), n (%) Low Middle High |
22 (14.47) 116 (76.32) 14 (9.21) |
| Clinical type of MS, n (%) PPMS SPMS PRMS RRMS |
9 (5.92) 13 (8.55) 5 (3.29) 125 (82.24) |
| Disease duration (years), n (%) 0–1 2–5 6–10 11–15 16–20 >20 |
6 (3.95) 51 (33.55) 48 (31.58) 29 (19.08) 11 (7.24) 7 (4.61) |
| Treatment, n (%) Only for specific MS symptoms Disease–modifying therapies |
27 (17.76) 125 (82.24) |
| Treatments to modify progression, n (%) Gilenia Extavia Copaxone Tecfidera Rebif Betaferon lub Betaseron Avonex Tysabri |
12 (9.60) 2 (1.60) 24 (19.20) 38 (30.40) 12 (9.60) 24 (19.20) 8 (6.4)0 5 (4.00) |
| Complains, n (%) Vision disorders Mobility and balance disorders Sphincter disorders Paresthesia. neuralgia Fatigability Dysphagia Hypertonia Speech disorders Sexual disorders Mood disorders |
72 (47.37) 104 (68.42) 78 (51.32) 61 (40.13) 136 (89.47) 14 (9.21) 57 (37.50) 14 (9.21) 52 (34.21) 89 (58.55) |
Abbreviations: RRMS, relapsing remitting MS; SPMS, secondary progressive MS; PPMS, primary progressive MS; PRMS, progressive–relapsing MS.